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Objective: To assess potential determinants of uptake and highlight lessons learnt from
the implementation of intermittent preventive treatment (IPTp), given to pregnant women
as early as possible during the second trimester in Zambia.
Methods: Data from four national malaria surveys (2006, 2008, 2010, 2012) were
reviewed, and proportions of pregnant women attending antenatal clinics (ANCs) who
received two or more doses of sulfadoxine–pyrimethamine (IPTp2) were compared by
place of residence, education level, and wealth status. Malaria cases and deaths in
pregnant women, from Health Information Management System 2011–2013, were
analyzed to determine malaria burden in pregnancy in Zambia. A multiple logistic
regression model was applied to identify potential determinants of IPTp uptake.
Results: The proportion of pregnant women who took IPTp at ANCs increased from
near zero at inception in 2001 to 61.9% in 2006; and to 72% by 2012 (P < 0.001), and
overall the uptake was 1.41 times higher in 2012 compared to 2006. From 2006 to 2012,
IPTp2 uptake among women with no formal education increased from 51% to 68%
(P < 0.1). Likewise, uptake among pregnant women with the lowest wealth index
increased from 58.2% to 61.2%. By 2012, IPTp uptake among pregnant women within
the lowest wealth index increased to a similar level as the women with high wealth index
(P = 0.05). Incidence of malaria cases, hospital admissions and mortality during preg-
nancy decreased between 2011 and 2013. Overall, increased IPTp uptake was associated
with being in urban areas (OR = 1.56, 95% CI: 1.39–1.74), having college (OR = 1.83,
95% CI: 1.25–2.75) or secondary education (OR = 1.68, 95% CI: 1.44–1.96) or of being
of higher wealth status (OR = 1.86, 95% CI: 1.60–2.17).
Conclusions: Zambia has increased IPTp uptake through ANC for all women. The
malaria control program has contributed to increasing access to health services and
reducing demographic and socioeconomic disparities.1. Introduction
Malaria infection during pregnancy is a major public health
problem in sub-Saharan Africa with signiﬁcant deleterious ef-
fects on the pregnant woman, her foetus and the newborn [1].article under the CC BY-NC-ND license (http://
Figure 1. Map of Zambia showing provinces [Source: google].
Figure 2. Population percentage distribution by Province, rural and urban
areas, Zambia, 2006–2010.
Source: Living conditions monitoring survey 2006–2010, Zambia.
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malaria in pregnancy differ depending on the level of
transmission intensity. In moderate-to-high stable malaria
transmission areas, women of reproductive age often have high
acquired immunity resulting in asymptomatic infections with
fewer cases of fever or clinical illness. More commonly, these
asymptomatic infections lead to maternal anaemia and low birth
weight, and a higher risk of infant mortality [2].
The World Health Organization (WHO) recommends a
package of interventions for prevention and control of malaria
during pregnancy in areas of stable transmission of Plasmodium
falciparum [3]. These interventions include: use of insecticide
treated nets or indoor residual spraying; chemoprevention with
three doses or more of intermittent preventive treatment (IPTp)
using sulfadoxine–pyrimethamine; parasitological diagnostic
testing and effective case management of malaria and anaemia
[4]. In 2012, WHO updated the malaria in pregnancy policy
for IPTp during pregnancy with sulfadoxine–pyrimethamine
and recommended that women who live in moderate-to-high
transmission areas should receive IPTp-sulfadoxine–pyrimeth-
amine as early as possible in the second trimester of gestation
and at each scheduled visit thereafter, provided that each sul-
fadoxine–pyrimethamine is given at least one month apart [5,6].
Zambia's preventive strategy for malaria in pregnancy aligns
with the WHO recommendations.
WHO Malaria Policy Advisory Committee recognized that in
many areas where parasites with quintuple mutations confer
antifolate resistance, IPTp with sulfadoxine–pyrimethamine still
maintained protective beneﬁts in terms of pregnancy outcomes
[6]. Despite these protective beneﬁts conferred by IPTp to
pregnant women, access to this life-saving intervention re-
mains limited in most countries in the sub-Saharan Africa [7].
Zambia adopted IPTp in 2001 with implementation starting in
2002 [8]. The IPT strategy in Zambia is delivered at antenatal
clinics (ANCs) as directly observed therapy.
Prior to the adoption of IPTp in 2001, the national malaria
control programme estimated malaria in pregnancy to contribute
about 20% of maternal deaths. However, with the recent
increased coverage of malaria interventions, it is expected that
the burden may have reduced [9]. Currently, Zambia is among
countries with the highest IPTp coverage in the sub-Saharan
African region at 73% (against the national target of 80%) [10].
Several years of consistent implementation of the IPTp-sul-
fadoxine–pyrimethamine strategy has yielded vital lessons for
preventing malaria in pregnancy in Zambia. However, there has
been no in-depth, systematic analysis of the strategy. As an early
adopter of the IPTp strategy [11], Zambia has gained important
lessons over the past decade that should be shared with other
countries in the sub-region. The purpose of this study is to
assess potential determinants of IPTp uptake and highlights
lessons learnt between 2006 and 2013.
2. Materials and methods
Data on IPTp were analyzed in the period 2006 to 2013. The
data sources were malaria surveys conducted in Zambia between
2006 and 2012 [12–15] and, routine data derived from Zambia's
District Health Management Information System records [16]
and national malaria programmatic gap analyses. Data on
population percentage distribution in rural and urban areas
were obtained from 2010 census of population and housing,
Zambia [17] derived from the Zambian provinces (Figure 1).In this regard, the focus of the IPTp analyses was on pregnant
woman who should have taken at least two or more doses of sul-
fadoxine–pyrimethamine antimalarial medicine during antenatal
care visits, as directly observed therapy, starting in the second
trimester of pregnancy [18]. Trend analyses on women, who
received at least two doses of IPTp, were carried out using the
Chi-squared test, at 5% level, to conﬁrm any signiﬁcant
difference in trends. The uptake of IPTp was compared between
rural and urban, education level and wealth index. The
classiﬁcation into rural and urban was based on an analysis by
the Department for International Development of the United
Kingdom, which takes into account several parameters, including
access to basic services-health, education (and other social ser-
vices) and population density [19]. Figure 2 shows the distribution
of the general population by province in Zambia [Data for
Muchinga Provincewas unavailable]. Educationwas classiﬁed into
four levels: none, primary, secondary and college, and the ﬁrst level
of education was used to compare uptake with the other education
levels. Wealth index was calculated based on the demographic and
health survey deﬁnition [20]. We then generated three levels: low,
medium and high wealth status. In all comparison, the Chi-square
was used. Furthermore, a multiple logistic regression of IPTp
uptake with year, rural/urban, education, wealth index and
province as explanatory variables was ﬁtted.
Table 3
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3.1. Population distribution
A total of 7664 (814 in 2006; 2392 in 2008; 436 in 2010 and
2022 in 2012) pregnant and those women who had given birth
prior to the survey were examined in 10 provinces of Zambia.
The total number of women examined in rural and urban was
7639 (Table 1), whereas 4672 women were examined by wealth
index: 457 in 2006; 1496 in 2008; 1529 in 2010 and 1190 in
2012.
3.2. Uptake of IPTp
The proportion of pregnant women attending ANCs who
received a second dose of sulfadoxine–pyrimethamine regard-
less of their social-economic status, increased from 61.9% in
2006 to 72.0% in 2012 (P < 0.001).
3.3. IPTp uptake in rural compared to urban women
Table 1 shows comparisons in the uptake of two doses of
sulfadoxine–pyrimethamine (IPTp2) among pregnant women
who attended at least one ANC between 2006 and 2012. During
this period, the uptake of IPTp2 among pregnant women in rural
areas increased from 58.1% (n = 616) in 2006 to (67.0%
(n = 1674) in 2012, P = 0.00. Likewise, in urban areas the
uptake increased from 71.2% (n = 198) in 2006 to 74.6%
(n = 323) in 2012 but the increase was not signiﬁcant (P = 0.45).
The IPTp2 uptake among women in rural areas was generally
lower than women in urban areas in 2006 (58.0% vs 71.2%); in
2008 (58.1% vs 65.2%); in 2010 (65.2%) vs 77.3%) and in 2012
(67.0% vs 74.6%).
3.4. Education levels and IPTp uptake
Table 2 shows IPTp2 uptake by levels of education in
Zambia between 2006 and 2012. During this period, the pro-
portion of women with no formal education who took IPTp2Table 1
Uptake of IPTp2 rural compared to urban among pregnant women who
attended at least one ANC, Zambia from 2006 to 2012.
Region Year P value
2006 2008 2010 2012 2006 vs
2012
Rural 616 (58.1) 1648 (58.1) 1595 (65.2) 1674 (67.0) 0
Urban 198 (71.2) 745 (65.2) 840 (77.3) 323 (74.6) 0.45
Table 2
Uptake of IPTp by education level among women attending antenatal
care in Zambia. n (%).
Year No. formal education Primary Secondary College
2006 148 (58.2) 479 (59.3) 174 (67.8) –
2008 387 (54.0) 1358 (58.8) 616 (66.9)* 30 (70.4)
2010 262 (63.0) 1301 (66.3) 798 (76.3)* 75 (72.6)
2012 346 (66.0) 1155 (67.6) 452 (73.7)* 44 (84.3)*
*: There is statistical signiﬁcant difference when primary, secondary and
college women compared with no formal education women; –: Data
unavailable for 2006 women in college.increased from 58.2% to 66.0% but the increase was not sig-
niﬁcant (P = 0.12). In general, women with no formal education
attending ANCs showed lower IPTp2 uptake than women hav-
ing secondary education, evident from 2008; 54.0% vs 66.9%
(P = 0.00); 63.0% vs 76.3% in 2010 (P = 0.00) and (66.0% vs
73.7%) in 2012 (P = 0.02). Similar statistically signiﬁcant dif-
ferences were notable between the women with no formal ed-
ucation compared to those with higher qualiﬁcation (college or
university) but a statistically signiﬁcant result was only observed
in 2012; For example, for the no formal education vs college,
compare 54.0% vs 70.4% in 2008 (P = 0.12); 63.0% vs 72.6% in
2010 (P = 0.16) and 66.0% vs 84.3% in 2012 (P = 0.02).
3.5. Wealth index and IPTp uptake
In 2006 uptake of IPTp2 in lowest wealth index category was
58.2% vs 61.2% in the highest wealth index (P = 0.73) among
pregnant women. However, by 2012 uptake among lowest
wealth index increased to 71.5%, a level similar to that in the
highest wealth index with 74.2% (P = 0.41).
3.6. Provincial variations in IPTp
In 2012, IPTp2 uptake reported in the Eastern Province
(85.4%) was comparable with that of Copperbelt Province
(85.3%), which has a higher population density and is more
urbanized than the Eastern. IPTp2 among women residing in
other rural provinces were generally lower than those experi-
enced in urban provincial areas. For example, compare 85.4%
IPTp2 reported in Copperbelt with 53.50% in Muchinga, 61.4%
in Western, 62.1% in North-Western Province and 76.00% in
Luapula Province.
3.7. Logistic regression model estimates
Table 3 presents estimates from the logistic regression.
Across the years, there was evidence of increased uptake of IPTpOdds ratios derived from a multiple logistic regression on the IPTp up-
take between 2006 and 2012 in Zambia.
Variable Odds ratio 95% CI
Year 2006 1.00
2008 0.95 0.80–1.12
2010 1.37 1.16–1.62
2012 1.41 1.19–1.68
Wealth index Low 1.00
Medium 1.19 1.03–1.37
High 1.86 1.60–2.17
Education None 1.00
Primary 1.14 0.99–1.30
Secondary 1.68 1.44–1.96
College 1.83 1.25–2.75
Residence Rural 1.00
Urban 1.56 1.39–1.74
Province Central 1.00
Copper belt 2.17 1.72–2.74
Eastern 1.07 0.87–1.30
Luapula 0.90 0.73–1.11
Lusaka 1.28 1.03–1.61
Northern 0.95 0.77–1.17
North western 1.27 0.98–1.63
Southern 0.65 0.53–0.79
Western 0.45 0.35–0.57
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uptake was 1.41 times higher, while in 2010 this was 1.37 times
higher compared to the uptake in 2006. The uptake in 2008
compared to that in 2006, showed no signiﬁcant difference. With
regards to wealth status, it was observed that women from high
and medium wealth households were more likely to access IPTp
compared to those in the low wealth status, with OR = 1.86
(95% CI: 1.60–2.17) for the high level, and OR = 1.19 (95% CI:
1.03–1.37) for those in the medium class.
Table 3 also shows that education level was an important
determinant for IPTp uptake. For women with secondary or
college education relative to those with no education, there was
increased uptake of IPTp, with the highest probability of uptake
among those who attained college education (OR = 1.83) fol-
lowed by those who achieved secondary education (OR = 1.68).
However, there was no evidence of difference between those
with primary education and those without education, despite
having OR = 1.14 in those with primary education. Comparing
women in rural and urban areas, those in urban areas were more
likely to access IPTp (OR = 1.56, 95% CI: 1.39–1.74) than those
in rural areas.
Turning to province of residence, there was distinct differ-
ences among provinces, with highest probability of uptake
observed in the Copperbelt province (OR = 2.17, 95% CI: 1.72–
2.74) and Lusaka province (OR = 1.28, 95% CI: 1.03–1.61)
compared to the Central province. On the other hand, women
from the Southern and Western provinces were less likely to
have increased uptake of IPTp compared to the Central province
(OR = 0.65, 95% CI: 0.53–0.79 and OR = 0.45, 95% CI: 0.35–
0.57, respectively). The other provinces: Eastern, Luapula,
Northern and North western did not show a signiﬁcant uptake of
IPTp compared to the Central province.
4. Discussion
This study suggests an increased uptake of IPTp, especially
for the second dose of sulfadoxine pyrimethamine (IPTp2)
among pregnant women attending antenatal clinics in rural lo-
cations of Zambia. In the study, women in both the lowest and
highest wealth index categories attained high IPTp2 uptake of
72% by 2012.
Zambia has a scattered population living in a large
geographical area with diverse terrain which makes the provi-
sion of universal coverage of health services to communities
challenging [21]. Therefore, improved uptake of IPTp in rural
settings reported in this study is a positive observation.
Increased uptake of preventive malaria services by women
with low social economic status and with limited formal edu-
cation in hard-to-reach rural areas underscores the important
contribution of malaria control programmes towards bridging
the rural and urban disparities and inequities in accessing ma-
laria health services in Africa [22]. Additional beneﬁts of IPTp in
improving uptake of other interventions in rural settings have
been documented in Uganda, located within Central Africa,
where increased uptake of ivermectin for the treatment of
onchocerciasis was demonstrated in rural settings where IPTp
services for malaria in pregnancy were introduced for pregnant
women [23].
Despite increasing trends of pregnant women's uptake of
IPTp in rural areas, disparities still exist among women
attending antenatal visits in rural and urban settings in Zambia.
Additionally, not all women attend all the recommended fourantenatal clinic visits. It has been observed that a large part of
the “unﬁnished business” in reproductive, maternal, newborn
and child health in the African region is related to addressing
inequities that seek to ensure that women and children receive
health services they need regardless of wealth, gender and ethnic
group [22]. Disparities in the provision of health services
between rural and urban communities are an important
impediment that negatively affects the attainment of national
and global goals and targets [24]. In 2012, the IPTp2 coverage
in rural provinces reached a high of 85% and was comparable
with uptake among women living in some urban provinces.
However, there were variations in IPTp uptake among the
rural provinces.
National uptake data of three doses of IPT remains low
among pregnant women in the African region [25]. In 2013,
among nine reporting countries, 17% of all pregnant women
received three or more doses of IPTp; 43% received two doses
and 57% received at least one dose of IPTp [25,26]. However, a
median of 89% of pregnant women in 31 reporting countries
attended ANC at least once among a total of 31 reporting
countries. In Zambia, 97% pregnant women attended at least
one ANC visit but only 72% took the recommended two or
more doses according to the Zambia Malaria Indicator Survey
2012 quoted under the materials and methods section.
The gap between the proportion of pregnant women
attending ANCs and those who receive IPTp is a missed op-
portunity for delivering all doses of IPTp in Zambia and other
sub-Saharan African countries. WHO has shown that the pro-
portion of women receiving at least one dose of IPTp increased
markedly from 2000 to 2007 but slowed between 2008 and 2013
for reasons yet to be identiﬁed [20,26].
In the current study, the observation that malaria accounted
for approximately 3% of reported deaths among the pregnant
women, attest to the protection conferred by interventions [27],
including IPTp implemented through focused antenatal care
that is integrated with reproductive health services.
The increasing trend in women's uptake of preventive in-
terventions such as IPTp at ANCs in rural and urban settings
with and without formal education underpins the positive
contribution of malaria control programmes towards increasing
uptake of health services and reducing disparities between rural
and urban women.
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